Category - Developments

Developments

NeuroSense, NeuraLight in pact to detect ALS oculometric biomarkers

NeuroSense Therapeutics (NASDAQ:NRSN) and closely-held NeuraLight are collaborating to advance the science of digital biomarkers in the detection and monitoring of neurological diseases, including amyotrophic lateral...

July 28, 2022

Developments

NervGen NVG-291-R posts significant preclinical functional repair from stroke

The University of Cincinnati and Case Western Reserve University published a pioneering preclinical study in the peer-reviewed scientific journal, Cell Reports, demonstrating that NervGen Pharma‘s (TSXV:NGEN;...

July 28, 2022

Developments

Palisade Bio screens first patient in Phase 3 bowel function trial

Palisade Bio (NASDAQ:PALI) screened the first patient in its Phase 3 study evaluating LB1148 to accelerate the return of bowel function in adult patients undergoing gastrointestinal surgery. “With the first U.S...

July 27, 2022

Developments

180 Life Sciences, U of Oxford to study post operative delirium

A team led by researchers at University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) in the U.K. to conduct a feasibility trial to investigate whether anti-tumor...

July 27, 2022

Developments

VistaGen fails Phase 3 trial in social anxiety disorder

VistaGen Therapeutics’ (NASDAQ:VTGN) topline results from its PALISADE-1 Phase 3 clinical trial of PH94B for the acute treatment of anxiety in adults with social anxiety disorder did not achieve its primary endpoint, as...

July 22, 2022

Developments

FDA clears Neuronetics TMS therapy for Anxious Depression

The FDA cleared a new indication for Neuronetics’ (NASDAQ:STIM) transcranial magnetic stimulation (TMS) system – NeuroStar Advanced Therapy for Mental Health – to treat anxiety symptoms for adult patients who suffer...

July 19, 2022

Developments

NICE recommends Rhythm’s IMCIVREE for treating obesity, controlling hunger

England’s National Institute for Health and Care Excellence (NICE) issued guidance that recommends Rhythm Pharmaceuticals’ (NASDAQ:RYTM) IMCIVREE as an option for treating obesity and controlling hunger caused by pro...

July 18, 2022

Developments

Soricimed Biopharma receives additional investment from NBIF

Closely held Soricimed Biopharma closed a $200,000 investment from the New Brunswick Investment Fund (NBIF) to continue developing its investigational SOR-13 oncology drug candidate. “We are grateful to NBIF for their...

July 13, 2022

Developments

Rhythm Pharma posts positive Phase 2 data in hypothalamic obesity

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported positive interim results from a Phase 2 clinical trial evaluating setmelanotide, its MC4R agonist, for the treatment of severe obesity and hyperphagia in people living with...

July 12, 2022

Developments

Annovis Bio gets FDA okay for Phase 3 Parkinson’s trial

Annovis Bio, Inc. (NYSE:ANVS) received notice from the FDA that a Phase 3 clinical study with buntanetap in early Parkinson’s patients may proceed. The FDA accepted the final protocol and the clinical development...

July 7, 2022

Category - Developments

Subscribe